Avalo Therapeutics, Inc. financial data

Symbol
AVTX on Nasdaq
Location
1500 Liberty Ridge Drive, Suite 321, Wayne, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.66K % +1977%
Quick Ratio 0.07 % -49%
Debt-to-equity 19.7 %
Return On Equity -88.4 % -372%
Return On Assets -73.9 % -716%
Operating Margin -15.5K % -993%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.1M shares +74.5%
Common Stock, Shares, Outstanding 17.8M shares +84.1%
Entity Public Float 12.9M USD +169%
Common Stock, Value, Issued 18K USD +80%
Weighted Average Number of Shares Outstanding, Basic 14M shares +152%
Weighted Average Number of Shares Outstanding, Diluted 14M shares +29.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
General and Administrative Expense 21.6M USD +47.1%
Costs and Expenses 66.7M USD +4.72%
Operating Income (Loss) -66.5M USD -5.78%
Nonoperating Income (Expense) -33.2M USD -161%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -99.7M USD -1152%
Income Tax Expense (Benefit) 149K USD
Net Income (Loss) Attributable to Parent -99.9M USD -1155%
Earnings Per Share, Basic 122 USD/shares +0.51%
Earnings Per Share, Diluted 131 USD/shares +31.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27M USD -67.1%
Cash, Cash Equivalents, and Short-term Investments 112M USD
Accounts Receivable, after Allowance for Credit Loss, Current 38K USD
Inventory, Net 0 USD -100%
Assets, Current 114M USD +32.2%
Operating Lease, Right-of-Use Asset 402K USD -64.7%
Goodwill 10.5M USD 0%
Assets 125M USD +27.1%
Accounts Payable, Current 474K USD -73.8%
Employee-related Liabilities, Current 3.38M USD +54.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 7.97M USD -86.9%
Deferred Income Tax Liabilities, Net 304K USD +97.4%
Operating Lease, Liability, Noncurrent 117K USD -89.2%
Other Liabilities, Noncurrent 117K USD -89.2%
Liabilities 33.6M USD -55.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 41K USD
Retained Earnings (Accumulated Deficit) -435M USD -29.8%
Stockholders' Equity Attributable to Parent 91.5M USD +334%
Liabilities and Equity 125M USD +27.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.46M USD -52.5%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 17.8M shares +84.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.46M USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 27.3M USD -66.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 65.7M USD +15.4%
Deferred Tax Assets, Gross 65.4M USD +15.2%
Operating Lease, Liability 555K USD -66%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30.6M USD -233%
Lessee, Operating Lease, Liability, to be Paid 595K USD -69.3%
Operating Lease, Liability, Current 438K USD -20.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 63K USD -88.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 392K USD -29.1%
Deferred Income Tax Expense (Benefit) 8K USD +14.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 40K USD -86.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 42.7M USD +14.5%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Additional Paid in Capital 526M USD +47.8%
Amortization of Intangible Assets 0 USD -100%
Depreciation, Depletion and Amortization 135K USD +297%
Share-based Payment Arrangement, Expense 12M USD +223%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%